Literature DB >> 7914486

Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis.

K Okuzawa1, B Franzén, J Lindholm, S Linder, T Hirano, T Bergman, Y Ebihara, H Kato, G Auer.   

Abstract

Fourteen human lung tumors of various histopathological types were subjected to two-dimensional gel electrophoresis (2-DE). Samples were prepared for 2-DE using a nonenzymatic sample preparation (NESP) technique recently established in our laboratory. Variations in the expression of some polypeptides were observed between tumors of different histopathological types. To this end, high expression of beta-tubulin, heat shock proteins 73 and 90, lamin B, and proliferating cell nuclear antigen (PCNA) were observed in small cell lung carcinomas (SCLC). One polypeptide of unknown identity (35 kDa, pI 5.5) was significantly overexpressed in primary lung adenocarcinomas compared with SCLC, squamous cell lung carcinomas, metastatic lung adenocarcinomas from colon and rectum, and normal tissue. The amino acid composition of this polypeptide is presented. In summary, combining the NESP technique and 2-DE is an effective approach to define tumor-specific markers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914486     DOI: 10.1002/elps.1150150157

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  10 in total

1.  Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis.

Authors:  U J Roblick; F G Bader; C Lenander; U Hellman; K Zimmermann; S Becker; A Ost; A Alaiya; H-P Bruch; R Keller; L Mirow; B Franzén; T Ried; G Auer; J K Habermann
Journal:  Int J Colorectal Dis       Date:  2008-02-22       Impact factor: 2.571

Review 2.  Proteomic biomarkers in lung cancer.

Authors:  M D Pastor; A Nogal; S Molina-Pinelo; A Carnero; L Paz-Ares
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

3.  Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.

Authors:  April Scott; Ravi Salgia
Journal:  Biomark Med       Date:  2008-12-01       Impact factor: 2.851

4.  Proteomic and bioinformatics analyses of mouse liver microsomes.

Authors:  Fang Peng; Xianquan Zhan; Mao-Yu Li; Fan Fang; Guoqing Li; Cui Li; Peng-Fei Zhang; Zhuchu Chen
Journal:  Int J Proteomics       Date:  2012-03-20

5.  Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins.

Authors:  B Franzén; S Linder; A A Alaiya; E Eriksson; K Uruy; T Hirano; K Okuzawa; G Auer
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

6.  Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features.

Authors:  T Hirano; K Fujioka; B Franzèn; K Okuzawa; K Uryu; H Shibanuma; K Numata; C Konaka; Y Ebihara; M Takahashi; H Kato; G Auer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A.

Authors:  T Hirano; G Auer; M Maeda; Y Hagiwara; S Okada; T Ohira; K Okuzawa; K Fujioka; B Franzén; N Hibi; T Seito; Y Ebihara; H Kato
Journal:  Jpn J Cancer Res       Date:  2000-10

Review 8.  [Research Progress of Biomakers Proteomics-based in Lung Cancer].

Authors:  Hui Xie; Zhengang Chen; Guangshun Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-06

9.  Expression of tropomyosin isoforms in benign and malignant human breast lesions.

Authors:  B Franzén; S Linder; K Uryu; A A Alaiya; T Hirano; H Kato; G Auer
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

10.  Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma.

Authors:  T Hirano; B Franzén; K Uryu; K Okuzawa; A A Alaiya; F Vanky; L Rodrigues; Y Ebihara; H Kato; G Auer
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.